Tevogen Logo Notified.png
Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference
18 juin 2024 15h17 HE | Tevogen Bio Inc
Untapped potential and development of a new class of T Cell therapies for large patient populations. Overcoming CAR-T challenges.
Tevogen Logo Notified.png
Tevogen Bio Set to Join Russell 3000® Index
12 juin 2024 15h45 HE | Tevogen Bio Inc
Tevogen Bio is set to join the Russell 3000® Index effective at the open of US equity markets on Monday, July 1.
Tevogen Logo Notified.png
Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
11 juin 2024 15h30 HE | Tevogen Bio Inc
Agreement for Up to $50 Million in Financing. Includes $36 million line of credit and potential $14 million private placement.
Tevogen Bio Social Engagement Event
CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event
07 juin 2024 15h32 HE | Tevogen Bio Inc
Tevogen social event aimed to understand patients' needs and discuss how its model could reduce healthcare costs and improve patient outcomes.
Tevogen Logo Notified.png
Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event
06 juin 2024 18h14 HE | Tevogen Bio Inc
Tevogen social event aimed to understand patients' needs and discuss how its model could reduce healthcare costs and improve patient outcomes.
Tevogen Logo Notified.png
Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2
06 juin 2024 15h52 HE | Tevogen Bio Inc
Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2
Tevogen Logo Notified.png
Tevogen Bio Reports First Quarter 2024 Financial Results
29 mai 2024 08h00 HE | Tevogen Bio Inc
Tevogen Bio first quarter '24 financial results: Liability elimination of $94.9M. $11.3M of net income. Net cash operations $2.1M. $36M LOC.
William Keane, Vice President of Strategic Initiatives, Tevogen Bio
Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives
16 mai 2024 14h00 HE | Tevogen Bio Inc
Former police chief & FBI National Academy graduate, William Keane, to work with functional leads, ensure policies, procure Tevogen’s lab space.
Tevogen Logo Notified.png
Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives
10 mai 2024 17h40 HE | Tevogen Bio Inc
$50 million in financing advances operational objectives and bolsters a financial path to positive cashflow with minimal dilution.
Tevogen Logo Notified.png
Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives
01 mai 2024 08h05 HE | Tevogen Bio Inc
For full year 2023, the operating expenses for Tevogen Bio Inc were $8.8 million.